Wockhardt Limited held an Investor Conference Meet/Call on Thursday, 4th June 2026, as disclosed in their regulatory filing dated 11th June 2026 (Ref. No.: WOCK/SEC/SE/2026-27/017). The event was a post-approval investor interaction following the US FDA approval of Zaynich, their novel antibiotic.

Event Details:

  • Type of Event: Investor conference meet/call with both in-person (at NSE Exchange Plaza) and virtual participation.
  • Date and Time: Thursday, 4th June 2026 (time not specified in the transcript).
  • Purpose: To share developments and milestones in the Wockhardt journey, particularly focusing on the US FDA approval and commercialization strategy for Zaynich, and to provide an overview of the organization's strategy and financial performance.

Management Participants:

The following management team members participated in the event:

  • Dr. Habil Khorakiwala – Founder Chairman
  • Dr. Huzaifa Khorakiwala – Executive Director
  • Dr. Murtaza Khorakiwala – Managing Director
  • Ms. Zahabiya Khorakiwala – Director
  • Dr. Mahesh Patel – Chief Scientific Mentor
  • Dr. Sachin Bhagwat – Chief Scientific Officer
  • Ms. Annapurna Das – President India Business and NCE Emerging Markets

Virtual participants from the US core team included:

  • Mr. William McNey – Chief Commercial Officer, Novel Antibiotics Business
  • Dr. Dennis Deruelle – Chief Medical Officer, US Novel Antibiotics Business
  • Mr. Leo Yasinski – Vice President, Market Access NCE Business
  • Ms. Sandy Estrada – Senior National Director, Field Medical and Medical Science Liaison

Presentation Content:

The session included presentations from Dr. Murtaza Khorakiwala (overview of the organization), Ms. Zahabiya Khorakiwala (US strategy for Zaynich), and Ms. Annapurna Das (strategy for emerging markets), along with video presentations.

Availability of Materials:

The company disclosed that the transcript of the investor meeting would be uploaded on the company's website at: https://www.wockhardt.com/wp-content/uploads/2026/06/wockhardt-investor-meet-jun-04-2026.pdf

Financial Highlights Discussed:

Management shared financial results for the year:

  • Top line: INR 3,373 crores
  • EBITDA: INR 630 crores (51% growth)
  • Profitability before tax: INR 238 crores
  • Cash equivalents: INR 662 crores
  • Net debt-to-equity ratio: 0.1
  • EBITDA margin improvement from 5.4% three years ago to 18.6% currently

Strategic Updates:

  • Zaynich is the first Indian research product approved by US FDA
  • Global launch strategy for Zaynich in US (2026), India (2026), Europe and emerging markets (subsequent years)
  • Biosimilar business grew 27% in current year, with production scale-up of human insulin (2x) and Glargine (1.5x)
  • Emerging market business grew 35% (28% of turnover)
  • UK business grew 13% (39% of total business)
  • Focus on three business pillars: pharmaceutical business (75% of business), biosimilar/biotech business, and novel antibiotic business

Forward-looking Statements:

  • Global peak sales potential for Zaynich: $1.5-2 billion
  • Expect breakeven for Zaynich business in 12-18 months
  • Capex plan of INR 200-300 crores over next three years, primarily for biologicals capacity
  • Plan to double biosimilar business in 24-36 months
  • Filed for European approval of Zaynich (expected by end of 2026)
  • Planning to launch in 7-8 emerging markets in next 18-24 months

Compliance Statement:

The document does not explicitly state that no unpublished price sensitive information (UPSI) will be shared, but it represents a formal regulatory disclosure of already-public information.

Additional Notes Section

The document includes the full transcript of the investor meeting with detailed Q&A session covering various aspects of the business strategy, market potential, execution risks, and financial projections.

No financial data was newly disclosed in this announcement beyond what was already presented in the investor meeting. The document serves as a regulatory filing of the meeting transcript.